Bolt Biotherapeutics Stock Price, News & Analysis (NASDAQ:BOLT) $0.93 +0.02 (+2.20%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.92▼$0.9550-Day Range$0.85▼$1.0752-Week Range$0.84▼$2.03Volume227,845 shsAverage Volume163,647 shsMarket Capitalization$35.32 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media Bolt Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside509.3% Upside$5.67 Price TargetShort InterestBearish6.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.66Based on 2 Articles This WeekInsider TradingSelling Shares$125,191 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.78) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector390th out of 948 stocksBiotechnology Industry12th out of 46 stocks 3.3 Analyst's Opinion Consensus RatingBolt Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, Bolt Biotherapeutics has a forecasted upside of 509.3% from its current price of $0.93.Amount of Analyst CoverageBolt Biotherapeutics has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.72% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 2.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BOLT. Previous Next 1.9 News and Social Media Coverage News SentimentBolt Biotherapeutics has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bolt Biotherapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for BOLT on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,191.00 in company stock.Percentage Held by Insiders28.40% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.56% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.78) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bolt Biotherapeutics Stock (NASDAQ:BOLT)Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More BOLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BOLT Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®November 28, 2023 | americanbankingnews.comBolt Biotherapeutics (NASDAQ:BOLT) Shares Cross Below Two Hundred Day Moving Average of $1.26December 6, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 11, 2023 | markets.businessinsider.comPromising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt BiotherapeuticsNovember 9, 2023 | morningstar.comBolt Biotherapeutics Inc Ordinary Shares BOLTNovember 9, 2023 | finance.yahoo.comBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 23, 2023 | finance.yahoo.comBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressOctober 17, 2023 | finance.yahoo.comBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersDecember 6, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. September 28, 2023 | finance.yahoo.comBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersSeptember 5, 2023 | finance.yahoo.comBolt Biotherapeutics to Participate in September Investor ConferencesAugust 3, 2023 | msn.comDynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass EstimatesJune 17, 2023 | finance.yahoo.comUS0977021049.SG - Bolt Biotherapeutics Inc.May 26, 2023 | markets.businessinsider.comBolt Biotherapeutics (BOLT) Receives a Buy from H.C. WainwrightMay 13, 2023 | msn.comSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)May 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy RecommendationMay 12, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)May 12, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingApril 11, 2023 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearMarch 30, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingJanuary 21, 2023 | reuters.comBOLT.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comHere's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn SituationNovember 2, 2022 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last yearNovember 1, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at Stifel 2022 Healthcare ConferenceSeptember 10, 2022 | morningstar.comBolt Biotherapeutics Inc Ordinary SharesSee More Headlines Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+509.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,100,000.00 Net Margins-990.43% Pretax Margin-990.43% Return on Equity-47.56% Return on Assets-35.64% Debt Debt-to-Equity Ratio0.14 Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$5.73 million Price / Sales6.16 Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book0.20Miscellaneous Outstanding Shares37,970,000Free Float27,184,000Market Cap$35.32 million OptionableNot Optionable Beta0.71 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Randall C. Schatzman Ph.D. (Age 68)CEO & Director Comp: $829.32kDr. Edgar George Engleman M.D. (Age 77)Founder & Independent Director Comp: $38.75kMr. William P. Quinn (Age 52)CFO & Secretary Comp: $594.56kMr. Grant Yonehiro C.F.A. (Age 59)M.B.A., Chief Business Officer Comp: $544.71kDr. Edith A. Perez M.D. (Age 66)Chief Medical Officer Comp: $668.32kMr. Wesley BurwellVP & Head of Human ResourcesDr. Nathan Ihle Ph.D.Senior Vice President of Pharmaceutical OperationsMore ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMCurisNASDAQ:CRISNRx PharmaceuticalsNASDAQ:NRXPInstil BioNASDAQ:TILProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsEdgar EnglemanSold 25,805 sharesTotal: $23,482.55 ($0.91/share)Edgar EnglemanSold 31,257 sharesTotal: $28,756.44 ($0.92/share)Vivo Capital Viii, LlcSold 54,700 sharesTotal: $50,324.00 ($0.92/share)Edgar EnglemanSold 8,571 sharesTotal: $8,228.16 ($0.96/share)Vivo Capital Viii, LlcSold 15,000 sharesTotal: $14,400.00 ($0.96/share)View All Insider TransactionsView All Institutional Transactions BOLT Stock Analysis - Frequently Asked Questions Should I buy or sell Bolt Biotherapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLT shares. View BOLT analyst ratings or view top-rated stocks. What is Bolt Biotherapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 12-month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 509.3% from the stock's current price. View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts. How have BOLT shares performed in 2023? Bolt Biotherapeutics' stock was trading at $1.30 at the start of the year. Since then, BOLT shares have decreased by 28.5% and is now trading at $0.9301. View the best growth stocks for 2023 here. When is Bolt Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BOLT earnings forecast. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.06. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $1.60 million. Bolt Biotherapeutics had a negative net margin of 990.43% and a negative trailing twelve-month return on equity of 47.56%. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). When did Bolt Biotherapeutics IPO? (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Bolt Biotherapeutics' major shareholders? Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Newtyn Management LLC (2.69%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP, Vivo Capital Viii, Llc and William P Quinn. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BOLT) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.